NATCOPHARM Stock Overview
A pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
NATCO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,243.00 |
| 52 Week High | ₹1,639.00 |
| 52 Week Low | ₹828.00 |
| Beta | 0.55 |
| 1 Month Change | -12.28% |
| 3 Month Change | -5.85% |
| 1 Year Change | 47.94% |
| 3 Year Change | 40.70% |
| 5 Year Change | 93.12% |
| Change since IPO | 6,805.56% |
Recent News & Updates
Investors Aren't Buying NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings
Dec 23
Is NATCO Pharma (NSE:NATCOPHARM) Using Too Much Debt?
Dec 08NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50
Nov 18Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 15Recent updates
Investors Aren't Buying NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings
Dec 23Is NATCO Pharma (NSE:NATCOPHARM) Using Too Much Debt?
Dec 08NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50
Nov 18Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 15We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
Oct 13NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Shareholder Returns
| NATCOPHARM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.1% | 1.5% | 3.4% |
| 1Y | 47.9% | 27.7% | 11.3% |
Return vs Industry: NATCOPHARM exceeded the Indian Pharmaceuticals industry which returned 27.7% over the past year.
Return vs Market: NATCOPHARM exceeded the Indian Market which returned 11.3% over the past year.
Price Volatility
| NATCOPHARM volatility | |
|---|---|
| NATCOPHARM Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: NATCOPHARM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: NATCOPHARM's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4,016 | Rajeev Nannapaneni | www.natcopharma.co.in |
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services.
NATCO Pharma Limited Fundamentals Summary
| NATCOPHARM fundamental statistics | |
|---|---|
| Market cap | ₹222.63b |
| Earnings (TTM) | ₹19.45b |
| Revenue (TTM) | ₹45.64b |
11.4x
P/E Ratio4.9x
P/S RatioIs NATCOPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NATCOPHARM income statement (TTM) | |
|---|---|
| Revenue | ₹45.64b |
| Cost of Revenue | ₹6.95b |
| Gross Profit | ₹38.69b |
| Other Expenses | ₹19.24b |
| Earnings | ₹19.45b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 108.58 |
| Gross Margin | 84.78% |
| Net Profit Margin | 42.61% |
| Debt/Equity Ratio | 2.8% |
How did NATCOPHARM perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield5%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 18:09 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NATCO Pharma Limited is covered by 27 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |